Pancreatic cancer is a lethal disease that remains one of the most resistant to traditional
therapies.
Immunotherapy in
pancreatic cancer induces the recruitment and activation of T cells that recognize
tumor-associated
antigens (TAAs); thus, the mechanism differs from that of
chemotherapy and
radiotherapy. The goal of
cancer immunotherapy is to elicit immune responses against autologous
tumors, and especially to induce multiple T cell clones against a variety of TAAs. In the present study, we prepared a polyvalent
tumor lysate
vaccine engineered to express the α-gal
epitopes, Galα1-3Galβ1-4 GlcNAc-R (i.e., α-gal
tumor lysate), from primary
tumors. The
vaccine elicited strong antibody production against multiple TAAs in
pancreatic cancer cells and induced activation of multiple
tumor-specific T cells in α1,3-galactosyltransferase (α1,3GT) knockout (KO) mice. The
tumor lysate
vaccine exhibited a similar effect on
pancreatic cancer stem cells (CSCs) with the CD44+CD24+ phenotype. Furthermore, in vivo experiments using NOD/SCID mice, inoculated with splenocytes from KO mice vaccinated with the α-gal
tumor lysate and injected with
pancreatic cancer cells, showed successful induction of a marked immune response that resulted in suppression of
tumorigenesis and significant improvement in overall survival. In contrast, inoculation of lymphocytes from KO mice vaccinated with control
tumor lysate
vaccine had no effects on
tumor growth and survival. The results of both in vitro and in vivo experiments emphasize the efficiency of
tumor lysate
vaccines expressing α-gal
epitopes in targeting all
pancreatic cancer cells, including differentiated
cancer cells and pancreatic CSCs. The α-gal
tumor lysate
vaccine could be the basis for a novel therapeutic approach in human clinical trials.